3 Ways Canopy Growth Corp (TSX:WEED) Is Overvalued

Canopy Growth Corp (TSX:WEED)(NYSE:CGC), the acknowledged leader in the cannabis industry, should focus more on its competitive advantages and set sensible revenue goals so as not to lose the trust of investors.

| More on:

Recently, I wrote about weed company Aphria’s ambitious $1 billion sales target and the difficulty of hitting that goal. This time, I heard a similar tune from Canopy Growth (TSX:WEED)(NYSE:CGC). Being the largest publicly traded weed stock in the world, the goal of $1 billion net revenue is not ill-conceived.

However, despite the $18.9 billion market cap and industry leader status, the chances of Canopy Growth missing the target are high. Enthusiastic investors might be in for another disappointing episode. But don’t tell that to Bill Newlands, CEO of Constellation Brands. The Corona beer maker CEO is exceedingly hopeful.

Tough call

You can’t tell if Mr. Newlands is serious or merely grandstanding about his optimistic view. Constellation Brands has $4 billion investment in Canopy Growth, which is equivalent to 38% ownership. But then again, it might be a sign of restiveness. The massive investment needs to start paying back soon.

The $1 billion net revenue target is a tough call. Cannabis sales in Canada are projected to be in the vicinity of $5-6 billion in 2019. The current sales seem to be along those figures. If Canopy Growth is bent on hitting Newland’s desired revenue, the company should deliver three times more than the latest net revenue.

Constellation Brands is also hoping to introduce cannabis-infused beverages and edibles by year-end. The new market might add a significant amount of revenue. But a major roadblock stands in the way. Health Canada is poised to implement licensing regulations.

Hence, Canopy Growth will be hard pressed to meet annualized revenue that is over and above $1 billion. The reality is that sales aren’t growing exponentially. Also, because of disenchantment and unpleasant experience with the Tweed brands, medical clients are shifting to less-costly unlicensed options.

By the end of the current fiscal year, annualized net revenue might double from the $332 million run rate Canopy achieved during the fourth quarter of 2018. For that to happen, though, the company needs to get awfully lucky.

The problem of oversupply

The cultivation potential of Canopy Growth is enormous. A peak annual production of 500,000 kilos is not far-fetched. The five largest farms will get the job done. Unfortunately, industry peers are also working double time to increase production capacities. The danger of oversupply looms large.

If the market is overflowing with cannabis, pricing pressure will be tremendous. The sharp drop in prices and reduced gross margins will weigh heavily on Canopy Growth and the rest of the cannabis-producing companies. You can throw away the dream of $1 billion annual sales out the window.

Mixed signals

The signals are mixed. You begin to wonder why some analysts still maintain a price target of $73.33 and an absurdly high estimate of $100. I’m not bursting anyone’s bubble. But the way things are going, Canopy Growth and other cannabis companies should come clean. It’s better to stick to realistic numbers than pluck them out of the air.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Should You Buy Canopy Growth Stock or Green Thumb Stock Today?

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Could Aurora Cannabis Stock Finally Recover by Year-End?

Down 99% from all-time highs, Aurora Cannabis stock is focused on improving profit margins and expanding sales of its medical…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Are Pot Stocks About to Surge Again? 

With pot stocks making big moves of late, many investors are now asking whether the cannabis sector is worth investing…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »